On Oct. 12, 2024, the Sabin Vaccine Institute announced it had delivered approximately 1,000 more investigational vaccine doses to Rwanda to bolster the ongoing response to the Marburg virus outbreak. This follows Sabin’s initial shipment of 700 Marburg vaccine doses on October 5, just nine days after the outbreak was declared.

Sabin has extensive expertise in advancing vaccines for filoviruses, with two programs currently in Phase 2 clinical trials—one for Marburg and the other for Sudan ebolavirus. Sabin is also a long-standing member of MARVAC, a WHO-coordinated consortium promoting international collaboration for the development of vaccines against Marburg virus disease.

Sabin’s development program, which includes clinical trials and manufacturing of clinical trial material that have been leveraged in this donation, is supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, under multi-year contracts. BARDA has to date obligated $235 million to Sabin for advancing vaccine research and development against Sudan ebolavirus and Marburg virus diseases.